SEC Comment Letter for Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281) (PLX) — Apr 22, 2020
Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281)
Date: April 22, 2020 · CIK: 0001006281 · Accession: 0000000000-20-003470
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-237736
Letter
April 22, 2020 Dror Bashan Chief Executive Officer Protalix BioTherapeutics, Inc. 2 Snunit Street, Science Park P.O. Box 455 Carmiel 2161401, Israel Re:Protalix BioTherapeutics, Inc. Registration Statement on Form S-3 Filed April 17, 2020 File No. 333-237736 Dear Mr. Bashan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brian Hirshberg, Esq.
Show Raw Text
April 22, 2020
Dror Bashan
Chief Executive Officer
Protalix BioTherapeutics, Inc.
2 Snunit Street, Science Park
P.O. Box 455
Carmiel 2161401, Israel
Re:Protalix BioTherapeutics, Inc.
Registration Statement on Form S-3
Filed April 17, 2020
File No. 333-237736
Dear Mr. Bashan:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Brian Hirshberg, Esq.